Oxaliplatin in Gastric Cancer

Inclusion Criteria: * ECOG performance status of 0-2. * Histologically proven gastric or gastro-esophageal junction adenocarcinoma. * At least unidimensional measurable disease. If a unique metastasis constitutes the only disease sign, it requires histological confirmation. * First line locally unresectable or metastatic gastric cancer. * Relapsing gastric cancer after local and/or systemic treatment with a post-surgical period of at least 4 weeks, a post-adjuvant or neoadjuvant chemoradiotherapy period of at least 6 months. * Serum bilirubin \< 2 mg/dl * Serum creatinine \< or = 2 mg/dl * Hemoglobin \> or = 10 g/dl * Absolute neutrophil count \> or = 2000/dl * Platelet count \>or = 100, 000/dl * AST/ALT \< or = 2.5 time-fold the institutional normal upper limit * Alkaline phosphatase \< or = 5 time-fold the institutional normal upper limit * Imagenological evaluation of the patient at least 2 weeks prior to the drug infusion * Laboratory tests at least 1 week prior to the first infusion * Patient available for follow up and able to answer to the quality of life questionnaire Exclusion Criteria: * Symptomatic sensorial peripheral neuropathy * Uncontrolled concomitant disease * Another malignant neoplastic disease diagnosed within the previous 5 years to the diagnosis of advanced or metastatic gastric cancer, with the exception of 'in situ' cervix carcinoma or non-melanoma skin cancer * Concomitant antitumoral treatment * Cerebral metastases * Unstable heart disease, even though in treatment * Myocardial infarction within the last 6 months * Radiotherapy within the last 6 weeks, surgery within the last 4 weeks, or chemotherapy within the last 6 months. * Pregnancy or nursing ( or women in reproductive life without adequate contraception) * Significant neurological or psychiatric disorders.